Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun;89(6):1820-1833.
doi: 10.1111/bcp.15644. Epub 2023 Jan 13.

Experience with sotrovimab treatment of SARS-CoV-2-infected patients in Denmark

Line Dahlerup Rasmussen  1 , Anne-Mette Lebech  2   3 , Anne Øvrehus  1 , Birgitte Klindt Poulsen  4 , Hanne Rolighed Christensen  5 , Henrik Nielsen  6   7 , Isik Somuncu Johansen  1 , Lars Haukali Omland  2 , Lothar Wiese  8 , Marie Helleberg  2   9 , Merete Storgaard  10 , Michael Dalager-Pedersen  6   7 , Thomas A Rasmussen  10   11 , Thomas Benfield  12 , Tonny Studsgaard Petersen  5 , Åse Bengård Andersen  2 , Mie Agermose Gram  13 , Marc Stegger  13 , Sofie Marie Edslev  13 , Niels Obel  2   3   14
Affiliations

Experience with sotrovimab treatment of SARS-CoV-2-infected patients in Denmark

Line Dahlerup Rasmussen et al. Br J Clin Pharmacol. 2023 Jun.

Abstract

Aims: To evaluate the experience with use of sotrovimab following severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in high-risk groups.

Methods: In a nationwide, population-based cohort study, we identified all individuals treated with sotrovimab (N = 2933) and stratified them by 4 high-risk groups: (A) malignant haematological disease, (B) solid organ transplantation, (C) anti-CD20 therapy ≤1 year and (D) other risks. Cox regression analysis was used to calculate hazard ratios for hospitalization, death and associated prognostic factors.

Results: Of 2933 sotrovimab-treated individuals, 83% belonged to high-risk groups (37.6% haematological malignancy, 27.4% solid organ transplantation and 17.5% treatment with anti-CD20 ≤1 year). Only 17.8% had other risks (11.8% were pregnant, 10.7% primary immunodeficiency, 21.2% other malignancy, 4.3% received anti-CD20 >1 year and 52.0% other/unknown causes). Within 90 days of infusion, 30.2% were hospitalized and 5.3% died. The main prognostic factors were the predefined high-risk groups, mainly malignant haematological disease and age ≥65 years. Number of COVID-19 vaccines (≥3) was associated with a decreased risk of hospitalization. The Delta but not the Omicron BA.2 variant was associated with a higher risk of death compared to the BA.1 variant.

Conclusion: More than 90% of the patients treated with sotrovimab belonged to the very high-risk groups as described in the Danish guidelines. Sotrovimab-treated individuals remained at a high risk of hospitalization and death which was strongly associated with the underlying immunocompromised state and age. Having received >3 COVID-19 vaccines was association with decreased risk of death and hospitalization.

Keywords: COVID-19; SARS-CoV-2; SARS-CoV-2 vaccines; mAB; sotrovimab.

PubMed Disclaimer

Conflict of interest statement

Marie Helleberg has participated in a number of advisory boards from the following companies (AstraZeneca, GSK, Jannsen, MSD, and Roche & Sobi).

All other authors declare no competing interests.

Figures

FIGURE 1
FIGURE 1
Risk of hospitalization: (A) by high‐risk group, (B) by age, (C) by sex, (D) by SARS‐CoV‐2 vaccine status, (E) by calendar year, (F) by variant subtype and (G) by time after a positive test
FIGURE 2
FIGURE 2
Risk of death: (A) by high‐risk group, (B) by age, (C) by sex, (D) by SARS‐CoV‐2 vaccine status, (E) by calendar year, (F) by variant subtype and (G) by time after a positive test
See this image and copyright information in PMC

References

    1. Onder G, Rezza G, Brusaferro S. Case‐fatality rate and characteristics of patients dying in relation to COVID‐19 in Italy. Jama. 2020;323(18):1775‐1776. doi:10.1001/jama.2020.4683 - DOI - PubMed
    1. Stokes EK, Zambrano LD, Anderson KN, et al. Coronavirus disease 2019 case surveillance ‐ United States, January 22–May 30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(24):759‐765. doi:10.15585/mmwr.mm6924e2 - DOI - PMC - PubMed
    1. Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID‐19‐related death using OpenSAFELY. Nature. 2020;584(7821):430‐436. doi:10.1038/s41586-020-2521-4 - DOI - PMC - PubMed
    1. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID‐19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. Jama. 2020;323(13):1239‐1242. doi:10.1001/jama.2020.2648 - DOI - PubMed
    1. Gupta A, Gonzalez‐Rojas Y, Juarez E, et al. Effect of Sotrovimab on hospitalization or death among high‐risk patients with mild to moderate COVID‐19: a randomized clinical trial. Jama. 2022;327(13):1236‐1246. doi:10.1001/jama.2022.2832 - DOI - PMC - PubMed